GoodRx to Announce Third Quarter 2025 Financial Results on November 4, 2025, with Conference Call Scheduled for November 5, 2025
GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-centric digital healthcare platform known for helping millions of Americans access affordable medications, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of U.S. financial markets on Tuesday, November 4, 2025.
The Company also confirmed that its management team will host a conference call and live webcast the following morning, Wednesday, November 5, 2025, beginning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time), to review its quarterly financial and operational performance and discuss its strategic outlook for the remainder of 2025 and beyond.
GoodRx has provided participants with multiple options to access the call. Investors and analysts who wish to join by phone may dial (800) 715-9871 approximately 10 minutes before the scheduled start time. The conference ID number is 9085550. A simultaneous live webcast will be available on the Company’s where presentation materials and other relevant documents will also be posted before the start of the call.
For those unable to listen to the live event, an archived version of the webcast will be available on the Company’s Investor Relations page roughly one hour after the conference call concludes. This replay will remain accessible for a limited period for investors and interested stakeholders.
Continued Focus on Affordable Access to Medication
Founded in 2011, GoodRx has grown to become one of the most recognized names in the U.S. digital health and pharmacy savings ecosystem. The company operates with a mission to help Americans find the lowest possible prices on prescription medications and healthcare services. Its platform allows consumers to compare medication prices across pharmacies, access discount coupons, and increasingly, manage their broader healthcare needs—from telehealth visits to pharmacy benefit management and provider insights.
As of mid-2025, GoodRx remains a key player in addressing the growing concern of rising prescription costs in the United States. The company’s data-driven platform covers more than 70,000 pharmacies nationwide and provides users with real-time information about pricing differences across retail and online providers. The goal remains consistent: to make healthcare more transparent and affordable for everyone.
Over the years, GoodRx has diversified its business model beyond its traditional prescription savings offerings. Through acquisitions and strategic partnerships, the company has expanded into areas such as pharmaceutical manufacturer solutions, telehealth, and patient engagement services. This diversification has enabled GoodRx to evolve from a price-comparison tool into a more comprehensive healthcare access platform that connects patients, providers, and pharmaceutical stakeholders.
What to Expect from the Upcoming Third Quarter 2025 Results
While the company has not provided preliminary guidance for the upcoming quarter, investors will be paying close attention to key performance indicators such as:
- Revenue Growth: GoodRx’s revenue trends over the last several quarters have reflected both competitive pressures in the digital health sector and renewed momentum in its prescription savings programs.
- Subscription Metrics: The company’s subscription offerings, including GoodRx Gold, continue to play a vital role in generating recurring revenue and customer loyalty. Updates on active subscriber counts will likely be a focal point for analysts.
- Pharma Manufacturer Solutions Performance: This segment, which allows pharmaceutical brands to connect directly with consumers through GoodRx’s digital platform, has been a growing part of the company’s business mix.
- Cost Management and Margins: As with many healthcare technology companies, investors will be looking for evidence of operational efficiency, improved margins, and disciplined spending.
- Outlook for Full-Year 2025: Management is expected to provide commentary on how the company is positioned for the final quarter of 2025, particularly regarding strategic initiatives, partnerships, and technology investments.
A Track Record of Innovation and Growth
GoodRx’s evolution has mirrored broader trends in the U.S. healthcare landscape, particularly the increasing consumerization of health services. By empowering consumers with price transparency and digital tools, the company has played a major role in reducing barriers to medication adherence.
Over the last several years, GoodRx has invested heavily in analytics, technology infrastructure, and product innovation. Its digital platform now aggregates billions of pricing data points annually and leverages proprietary algorithms to identify the most affordable options for users.
In addition to consumer savings, GoodRx provides healthcare professionals with data insights that help them make cost-effective prescribing decisions. This dual-sided approach—to serve both patients and providers—has strengthened its ecosystem and made it an indispensable partner within the healthcare value chain.
The Broader Market Context
The upcoming third quarter earnings announcement will come at a pivotal moment for the healthcare technology sector. With inflationary pressures, evolving regulatory landscapes, and heightened competition in digital pharmacy and telehealth, companies like GoodRx are navigating both challenges and new opportunities.
Digital healthcare adoption remains strong, with more consumers seeking online solutions for prescription fulfillment, telemedicine, and care management. However, increased competition from retail pharmacy chains, PBMs (pharmacy benefit managers), and other technology entrants has required continuous innovation and differentiation.
GoodRx’s strategy has been to maintain a clear focus on its core mission—simplifying access to affordable medications—while expanding its influence in adjacent markets such as manufacturer marketing and patient adherence programs.
Investor and Analyst Engagement
GoodRx’s investor relations team continues to emphasize transparency and accessibility. The company has historically provided detailed financial disclosures, including breakdowns of its revenue streams and progress toward long-term growth initiatives.
The November 2025 conference call is expected to feature remarks from key executives, including Co-Founders and Co-CEOs Trevor Bezdek and Doug Hirsch, as well as Chief Financial Officer Karsten Voermann. They are likely to discuss quarterly performance highlights, recent product developments, and strategic priorities heading into 2026.
Analysts typically use these quarterly calls to gain insight into:
- Evolving prescription savings trends and consumer adoption patterns.
- The impact of new partnerships with pharmacy chains and healthcare providers.
- Performance within the company’s B2B pharmaceutical solutions segment.
- The company’s approach to technology development and AI-driven personalization.
The question-and-answer session that follows management’s prepared remarks will provide additional opportunities for investors and analysts to probe into the company’s financial trajectory and competitive positioning.
